Journals
Publish with us
Publishing partnerships
About us
Blog
Journal of Thyroid Research
Journal overview
For authors
For reviewers
For editors
Table of Contents
Special Issues
Journal of Thyroid Research
/
2011
/
Article
/
Tab 1
/
Review Article
Medullary Thyroid Carcinoma: Molecular Signaling Pathways and Emerging Therapies
Table 1
Some of the TKIs currently used for the treatment of MTC in clinical trials and off-label.
Drug
Oral daily dose
Major targets
Vandetanib
100–300 mg
VEGFR-1, VEGFR-2, VEGFR-3, RET, EGFR
Sorafenib
400–800 mg
RET, VEGFR-2, VEGFR-3, Flt-3, PDGFR
β
, KIT, RAF-1
Sunitinib
37.5 mg every day
50 mg daily 4 weeks on 2 weeks off
VEGFR-2, PDGFR
β
, KIT, RET
Cabozantinib (XL184)
125–175 mg/day
MET, VEGFR-2, RET, KIT, Flt-3, Tie-2
E7080
24 mg
VEGFR-2, VEGFR-3, VEGFR-1, KIT, FGFR1, PDGFR, EGFR